METOPROLOL TARTRATE INJECTION USP SOLUTION

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

METOPROLOL TARTRATE

Доступно од:

STERIMAX INC

АТЦ код:

C07AB02

INN (Међународно име):

METOPROLOL

Дозирање:

1MG

Фармацеутски облик:

SOLUTION

Састав:

METOPROLOL TARTRATE 1MG

Пут администрације:

INTRAVENOUS

Јединице у пакету:

10 X 5 ML

Тип рецептора:

Prescription

Терапеутска област:

BETA-ADRENERGIC BLOCKING AGENTS

Резиме производа:

Active ingredient group (AIG) number: 0111923004; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2016-06-15

Карактеристике производа

_ Metoprolol Tartrate Injection USP _
_Page 1 of 45_
PRODUCT MONOGRAPH
Pr
METOPROLOL TARTRATE INJECTION USP
5 mg / 5 mL (1 mg / mL) Solution
ß-Adrenergic Receptor Blocking Agent
SteriMax Inc.
2770 Portland Drive
Oakville, ON
Canada L6H 6R4
Date of Revision:
November 23, 2020
Submission Control No: 244731
_Metoprolol Tartrate Injection USP _
_Page 2 of 45_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
.............................................................................................................
12
DRUG INTERACTIONS
.............................................................................................................
15
DOSAGE AND ADMINISTRATION
.........................................................................................
21
OVERDOSAGE
...........................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
24
STORAGE AND
STABILITY………………………………………………………………….
27
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 29
PART II: SCIENTIFIC INFORMATION
...........................................................................................
30
PH